Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Kintor Reports Positive Data from Trial of Androgenetic Alopecia/Acne Therapy

publication date: Feb 10, 2023

Kintor, a Suzhou biopharma developing androgen products, reported positive top-line data from a US Phase I trial of a degrading androgen receptor candidate for androgenetic alopecia and acne. Kintor’s GT20029 is an in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. The trial data showed GT20029 was safe, well tolerated and had good pharmacokinetic characteristics in healthy subjects as well as subjects with androgenetic alopecia or acne. Kintor said GT20029 is the first topical PROTAC compound in the world to complete Phase I trials in both China and the US. More details....

Stock Symbol:(HK: 9939)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital